Treating high-risk bladder cancer after surgery
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two drugs (sacituzumab govitecan and nivolumab) given after surgery to prevent the return of muscle-invasive bladder cancer. It is for patients whose cancer has a high chance of coming back despite surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You had surgery to remove your bladder or kidney and ureter within the last 6 months.
- Your cancer was muscle-invasive and came from the bladder, ureter, or kidney pelvis.
- You have no signs of cancer on scans after surgery.
- You are in generally good health (able to care for yourself) and your blood counts and organ function meet study levels.
- You have not previously received immunotherapy (PD-1/PD-L1 inhibitors) or the drug sacituzumab govitecan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if sasanlimab, an immunotherapy drug, can help prevent bladder cancer from coming back after initial chemotherapy and before bladder removal surgery. It is for people with muscle-invasive bladder cancer that has not spread.
This trial tests a new drug called sacituzumab tirumotecan for people with low-grade bladder cancer that hasn't spread into the bladder muscle. The goal is to see if it can help shrink or control the tumors.
This trial tests a combination of two drugs, sacituzumab govitecan and zimberelimab, to treat muscle-invasive bladder cancer without removing the bladder. It's for patients who cannot or choose not to have bladder removal surgery or standard chemotherapy.
This Phase 1 study tests whether a new bladder-cancer treatment plan—radiation given at the same time as sacituzumab govitecan—can help people with muscle-invasive bladder cancer without starting with traditional chemo/radiation. Because it’s early-stage, the main goal is safety and learning the best way to use this combination to preserve the bladder.
This trial tests sacituzumab govitecan, an anti-cancer drug, for people with urothelial (bladder/urinary tract) cancer that has spread or can’t be removed with surgery. It’s designed for tumors that have been treated already in specific ways, to see if the medicine can shrink or control the cancer.
This trial tests a new drug combination (pembrolizumab and sacituzumab govitecan) against standard treatment for advanced bladder cancer that has spread or cannot be removed by surgery. It's for people who have already tried an immunotherapy drug like pembrolizumab and another drug called enfortumab vedotin.
Hear when a new Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.